I'll still take her over Russia's equivalent any day -- Mr. Putin can keep his Elvira, Mistress of the Dark
-- but yesterday Janet Yellen did endure a decidedly difficult debut as Fed head. Dow Industrials
(INDEXDJX:.DJI) swiftly dropped by triple digits after she spoke a muddled message. Clearly, Ms. Yellen is taking communications lessons from her fellow Brooklynite Shoshanna.
(Hey, as the first rule of journalism is "Sho, don't tell," I have some sympathy.) Among stocks on the move, Munich motormouth Bayerische Motoren Werke
(OTCMKTS:BAMXY) -- that's BMW for those of us who can't afford its $10 words -- bucked the Fed's ineffectual jawboning by surging 5.79% to the highest level in its history. With ego-swelling gains like those, I fear that its owners may eventually become total jerks
. Margaret Thatcher, who always knew how to put the Germans in their place
, could at least take some celestial solace in the showing of Rolls-Royce
(OTCMKTS:RYCEY). The company she put on a road to riches in the '80s bucked a remorseless tide of red ink elsewhere, advancing 0.25% on a broker boost
Today in economics, February existing home sales and leading indicators, along with the Philadelphia Fed index for March, are all out at 10:00 a.m. Eastern. Expect corporate earnings announcements from ConAgra Foods
(NYSE:CAG), Lennar Homes
(NYSE:LEN), and Nike
(NASDAQ:ARUN): This endless winter finally finishes, folks
, today at 12:57 p.m. Eastern, and with it the prime time to visit the Caribbean has passed. Or at least Aruba, which is assigned only a lukewarm Neutral at Macquarie. The target price is $22.
(NYSE:CRL): KeyBanc Capital Markets has a Hold on CRL.
(NASDAQ:SCOR): Shares are begun with a Buy recommendation and $40 price objective at Brean Capital, which says DoubleClick's ad server could be beneficial to ComScore's growth.
(NASDAQ:MSTR): The stock is a new Neutral at B. Riley & Co, whose target is $130.
(NASDAQ:REPH): Brean Capital begins a Buy and $26 objective on the equity amid potential for its principal product Dex-IN, an intranasal alpha-2 agonist to treat post-operative pain.
(NYSE:RKUS): RKUS gets resumed with an Outperform at Macquarie.
: Applied Materials
(NASDAQ:AMAT) and Lam Research
(NASDAQ:LRCX) are both begun with Buys at Nomura.
(NASDAQ:ZIOP): Mizuho assigns a Buy, and $11 objective, on a small-cap company it says offers promise in oncology-related synthetic biology technologies.
Stock Upgrades: From Russia With Love? Yum Brands Is Good Enough for Gorbachev
Stock Downgrades: Analyst Is So Over Under Armour
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.